Multiple Sclerosis Clinical Trial
— E-SEPOfficial title:
e-SEP Cognition: Effectiveness of a Remediation Program Via a "Serious Game" on the Cognitive Functions of Multiple Sclerosis Patients: Controlled, Randomized, Multicentric Trial
NCT number | NCT04694534 |
Other study ID # | RC-P0066 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 8, 2021 |
Est. completion date | March 1, 2026 |
The main goal of this study is to assess the effectiveness of a cognitive remediation program based on a "serious game" on the information processing speed evolution and the process of learning via episodic memory in multiple sclerosis patients.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | March 1, 2026 |
Est. primary completion date | March 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Relapsing-remitting or progressive multiple sclerosis people defined according to Mc Donald's criteria revised in 2005 - Age between = 18 and = 65 years old - Cognitive complaint, with at least one deficient score at the initial neuropsychological examination (<5th percentile of the reference group), one of the scores of which concerns at least one BICAMS test - Have not had a definite relapse for at least 6 weeks - Be at least 4 weeks away from a corticosteroid bolus - Lack of neuroleptic treatment - Patient with an Internet connection - Signed informed consent Exclusion Criteria: - Severe cognitive deficit defined by obtaining a deficit score in more than six cognitive processes at the initial neuropsychological assessment. - Neuropsychological care - Inability to receive oral and written information - Inability to use the software (due in particular to motor and / or sensory difficulties), - Neurological or psychiatric comorbidity, other than MS and anxiodepressive syndrome - Patient with severe anxiodepressive syndrome (BDI> 27) - Participation in an interventional study on cognitive functions - Patient under legal protection, guardianship or curatorship - Pregnant or breastfeeding women |
Country | Name | City | State |
---|---|---|---|
France | CH d'Arras | Arras | Nord Pas De Calais |
France | CH LENS | Lens | Nord Pas De Calais |
France | CHRU | Lille | Nord Pas De Calais |
France | Saint Vincent hospital | Lille | Nord Pas De Calais |
France | Saint-Philibert hospital | Lomme | Nord |
France | Charles Nicolle Hospital | Rouen | Normandie |
Lead Sponsor | Collaborator |
---|---|
Lille Catholic University |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the California Verbal Learning Test (CVLT) | The California Verbal Learning Test (CVLT) begins with the examiner reading a list of 16 words. Patients listen to the list and report as many of the items as possible. | Change from baseline at 4 and 10 months | |
Primary | Change in the Brief Visuo-spatial Memory Test (BVMT) | In the Brief Visuospatial/lMemory Test six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. Thus, scores range from 0 to 12. | Change from baseline at 4 and 10 months | |
Primary | Change in the Symbol Digit Modalities Test (SDMT) | The Symbol Digit Modalities Test (SDMT) presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Patients are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure: the number correct. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Auditory-verbal spans in direct or reverse order | This assessment is required to evaluate short time memory and working memory. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Stroop Color-Word Test | This assessment is required to evaluate inhibition capacities and sensitivity to interference. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Trail Making Test | This assessment is required to evaluate cognitive flexibility abilities. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Categorical and phonemic verbal fluency test | This test is required to evaluate the spontaneous flexibility abilities. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Tower of London test | This test is required to assess planning capacities. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Commission test | This test assesses planning skills in a greener context than the Tower of London test. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Concentrated Attention Test | This assessment is required to evaluate selective attention. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Paced Auditory Serial Addition Task (PASAT) | This assessment is required to evaluate information processing speed and sustained attention. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Mac Nair Scale | This self-evaluation is required to assess cognitive complaint. It is a 39-items questionnaire corresponding to symptoms. Every symptom is noted on an ordinal scale in 5 steps.It is a scale with 5 degrees of severity measuring the frequency of disorders as follows: 4 = very often, 3 = often, 2 = sometimes, 1 = rarely, 0 = never. | Change from baseline at 4 and 10 months | |
Secondary | Change in the IPA (Participation and Autonomy Impact) Form | This test is focused on the subject social participation and autonomy. is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. The standard cut-off scores are as follows:
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. |
Change from baseline at 4 and 10 months | |
Secondary | Change in the BDI-II Scale (Beck Depression Inventory II) | This scale is required to assess participants depressive orders. This is a 21-items self-questionnaire. Every item is rated from 0 (no problem) to 3 (maximum symptom severity). The depressive syndrome severity total score presents 4 intensity levels : 0-11 (no depression), 12-19 (mild depression), 20-27 (medium depression), 27 (severe depression). | Change from baseline at 4 and 10 months | |
Secondary | Change in the State-Trait Anxiety Inventory (STAI Y) | This scale is used to evaluate the participants level anxiety. It is a 20-items questionnaire. The patients identifie the frequency with which they usually feel the symptoms listed on a four-point Likert-type scale variant from 1: "never" on the 1 point side to 4: "always" on the 4 point side.
The overall score varies between 20 and 80. |
Change from baseline at 4 and 10 months | |
Secondary | Change in the Visual Analogue Scale for Fatigue | This scale allows patients to assess their fatigue. The patients locate their fatigue intensity on a 100-millimeters horizontal line.Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. | Change from baseline at 4 and 10 months | |
Secondary | Change in the Apparent validity | Face validity is based on a subjective assessment of the instrument's validity to assess the patient's attitude towards the tool, its degree of involvement and its acceptability. | Change from baseline at 4 and 10 months | |
Secondary | Change in the EDSS score (Expanded disability status scale) | This score is required to assess the patients functional and neurological level disability. This scale stretchs from 0 (no complaint and normal examen) to 10 (death caused by MS). The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. | Change from baseline at 4 and 10 months | |
Secondary | Frequency of game play per Week (in days) | This outcome is required to evaluate the instructions observance and play practices. | Observance at 4 months | |
Secondary | Game session lenght | This outcome is required to evaluate the instructions observance and play practices. | Observance at 4 months | |
Secondary | Time spent gaming | This outcome is required to evaluate the instructions observance and play practices. | Observance at 4 months | |
Secondary | Game performance : tests number per exercise | This outcome is required to evaluate the instructions observance and play practices. The performance will be evaluated by the tests number per exercise. | Observance at 4 months | |
Secondary | Game performance : difficulty levels | This outcome is required to evaluate the instructions observance and play practices. The performance will be evaluated by the difficulty levels. | Observance at 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |